Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Alaunos Therapeutics (TCRT) Return on Sales (2016 - 2025)

Alaunos Therapeutics (TCRT) has disclosed Return on Sales for 13 consecutive years, with 678.83% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Return on Sales rose 132233.0% year-over-year to 678.83%, compared with a TTM value of 678.83% through Sep 2025, up 132233.0%, and an annual FY2024 reading of 481.2%, up 675640.0% over the prior year.
  • Return on Sales was 678.83% for Q3 2025 at Alaunos Therapeutics, down from 672.83% in the prior quarter.
  • Across five years, Return on Sales topped out at 5408.0% in Q3 2023 and bottomed at 7949.0% in Q4 2023.
  • Average Return on Sales over 5 years is 961.51%, with a median of 291.5% recorded in 2024.
  • The sharpest move saw Return on Sales crashed -881609bps in 2023, then surged 776025bps in 2024.
  • Year by year, Return on Sales stood at 5903.5% in 2021, then skyrocketed by 115bps to 867.09% in 2022, then plummeted by -1017bps to 7949.0% in 2023, then surged by 98bps to 188.75% in 2024, then tumbled by -260bps to 678.83% in 2025.
  • Business Quant data shows Return on Sales for TCRT at 678.83% in Q3 2025, 672.83% in Q2 2025, and 546.0% in Q1 2025.